logo-loader
HealthCannabis
Canntab Therapeutics Ltd

Canntab's plans boosted by initial indication of patentability for its immediate release CBD formulation

Canntab has successfully created a line of patent-pending precision oral delivery hard tablets

Canntab Therapeutics Ltd -
Canntab has filed 13 patents in Canada and the United States that cover a range of the processes and formulations it needs to create its hard tablets

Canntab Therapeutics Limited (CSE:PILL) (OTCMKTS:CTABF), the cannabis pill developer, has received a boost to its commercialization plans, it revealed Thursday, with a positive finding of patentability for its immediate release cannabidiol formulation.

Canntab has successfully created a line of patent-pending precision oral delivery hard tablets. The  technology means the company can convert THC and CBD oil into a nano-emulsified granulation, and ultimately into a hard pill format.

READ: Canntab Therapeutics making final steps towards bringing its products to market

Now, Geneva-based IPRP (the International Preliminary Report on Patentability) has indicated a positive finding of patentability, meaning that, in its opinion, Canntab's formulation is not only patentable but also "novel, non-obvious and useful."

Canntab noted that although the opinions of the IPRP are not binding, many patent offices, including Canada's for example, often defer to the IPRP.

"In fact, the Canadian office of the IPRP was also the international searching authority in this particular case, which bodes well for an eventual Canadian patent grant," it said in a regulatory statement.

"This is a first and an important indication that our Immediate Release Cannabidiol Formulation is unique and patentable. It is our intention to build on this success as we continue to seek additional patents in Canada, United States and internationally," said Jeff Renwick, co-founder and CEO of Canntab. 

Extensive portfolio

"Our extensive portfolio of proprietary hard tablets is our core value proposition and we believe that we are well positioned to be the dominant player in hard tablet cannabinoid formulations worldwide."

Canntab has filed 13 patents in Canada and the United States that cover a range of the processes and formulations it needs to create its oral delivery hard tablets.

These patents include its proprietary nano-emulsification technology, granulation process, methods of manufacturing, and covers its full line of precision oral delivery hard tablets including; Immediate release tablets, extended release tablets, sustained release tablets, Bi-Layered (Modified Release) tablets and flash melt formulations.

Contact the author at [email protected]

Quick facts: Canntab Therapeutics Ltd

Price: $0.60

Market: CSE
Market Cap: $15.18 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Canntab Therapeutics Ltd named herein, including the promotion by the Company of Canntab Therapeutics Ltd in any Content on the Site, the...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Full interview: Canntab receives indication of patentability for its release...

Canntab Therapeutics (CSE:PILL.CN-OTCQX: CTABF) Chief Financial Officer Richard Goldstein joined Steve Darling from Proactive Investors Vancouver on Skype with news that the company has received an initial assessment from the Geneva-based International Preliminary Report on Patentability...

on 08/15/2019

2 min read